Halozyme Therapeutics - HALO Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.

7 brokerages have issued 1 year price objectives for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $59.63 in the next year. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.

Halozyme Therapeutics' stock was trading at $56.90 at the beginning of 2023. Since then, HALO stock has decreased by 9.0% and is now trading at $51.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our HALO earnings forecast.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.49 by $0.21. The biopharmaceutical company earned $208.98 million during the quarter, compared to the consensus estimate of $187.87 million. Halozyme Therapeutics had a net margin of 36.37% and a trailing twelve-month return on equity of 134.71%.

Halozyme Therapeutics updated its FY23 earnings guidance on Tuesday, January, 10th. The company provided earnings per share guidance of $2.50-2.65 for the period, compared to the consensus estimate of $2.93. The company issued revenue guidance of $815-845 million, compared to the consensus revenue estimate of $892.43 million.

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.96%), Bernzott Capital Advisors (0.33%), Redwood Investments LLC (0.33%), Allspring Global Investments Holdings LLC (0.29%), Scout Investments Inc. (0.21%) and Assenagon Asset Management S.A. (0.12%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HALO stock can currently be purchased for approximately $51.77.

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $7.00 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $1.49 on an earnings per share basis.

The company employs 145 workers across the globe.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.